Published in Int J Oncol on August 21, 2012
A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int (2013) 1.02
BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. BMC Cancer (2015) 0.80
Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup. Biomark Res (2015) 0.79
Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (2010) 10.61
Biallelic inactivation of BRCA2 in Fanconi anemia. Science (2002) 9.31
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst (2006) 6.73
Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst (2002) 6.58
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science (2002) 6.32
American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol (2010) 4.93
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet (1997) 4.16
BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer (2011) 3.85
Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet (2001) 3.75
Purified human BRCA2 stimulates RAD51-mediated recombination. Nature (2010) 3.45
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
Genetic susceptibility to breast cancer. Mol Oncol (2010) 2.52
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol (2007) 2.19
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet (2006) 2.10
A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer (2004) 1.96
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer (2011) 1.86
Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators. J Clin Oncol (2008) 1.81
Deficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblasts. Cancer Res (2002) 1.60
Unraveling the mechanism of BRCA2 in homologous recombination. Nat Struct Mol Biol (2011) 1.59
Understanding missense mutations in the BRCA1 gene: an evolutionary approach. Proc Natl Acad Sci U S A (2003) 1.55
Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics (1999) 1.52
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat (2010) 1.40
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer (2012) 1.39
Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene (2002) 1.38
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat (2006) 1.34
The BRC repeats of human BRCA2 differentially regulate RAD51 binding on single- versus double-stranded DNA to stimulate strand exchange. Proc Natl Acad Sci U S A (2009) 1.30
Unclassified variants in BRCA genes: guidelines for interpretation. Ann Oncol (2011) 1.27
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res (2010) 1.26
Two modules in the BRC repeats of BRCA2 mediate structural and functional interactions with the RAD51 recombinase. Nucleic Acids Res (2009) 1.21
BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist (2007) 1.19
TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Cancer Res (2002) 1.17
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer (2003) 1.11
Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum Mol Genet (1999) 1.11
Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res (2011) 1.11
EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients. Hum Mutat (2011) 1.08
Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains. PLoS Genet (2011) 1.02
Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J (2007) 1.02
A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer. Fam Cancer (2011) 0.99
BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet (2006) 0.98
Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer (2006) 0.95
A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer. BMC Cancer (2007) 0.94
Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer. Gynecol Oncol (2005) 0.93
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece. Hered Cancer Clin Pract (2011) 0.90
Maspin is a tumour suppressor that inhibits breast cancer tumour metastasis in vivo. Breast Cancer Res (2002) 0.87
Clinical implications for BRCA gene mutation in breast cancer. Mol Biol Rep (2011) 0.84
BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells. Gynecol Oncol (2009) 0.83
Comparative disease pattern of a patient with a novel BRCA2 truncation and knockout models for BRCA2. Breast Cancer Res Treat (2010) 0.82
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study. Tumori (2006) 0.81
Time to reconsider subcutaneous mastectomy for breast-cancer prevention? Lancet Oncol (2005) 0.80
The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. BMC Med Genet (2011) 0.80
Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia. Gene (2012) 0.79
[Analysis of BRCA2 gene mutations among familial and/or early-onset breast cancer patients in eastern Shandong of China]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2008) 0.79
Contribution of BRCA2 germline mutations to hereditary breast/ovarian cancer in Germany. J Med Genet (2002) 0.78
Fanconi anemia gene mutations are not involved in sporadic Wilms tumor. Pediatr Blood Cancer (2010) 0.77
Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection. Fam Cancer (2010) 0.77
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol (2013) 6.79
Lower incidence of anaplastic carcinoma after higher iodination of salt in Slovenia. Thyroid (2010) 1.53
A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17
Papillary thyroid microcarcinoma: prognostic factors and treatment. J Surg Oncol (2008) 1.15
Programmable ultrasonic sensing system for targeted spraying in orchards. Sensors (Basel) (2012) 1.15
Pneumomediastinum, pneumopericardium, and pneumoperitoneum caused by peridiverticulitis of the colon: report of a case. Dis Colon Rectum (2004) 1.12
Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nat Genet (2012) 1.10
KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study. BMC Cancer (2012) 1.01
Changing biology of cutaneous melanoma. Melanoma Res (2008) 0.90
Isolation, characterization and differentiation of cells expressing pluripotent/multipotent markers from adult human ovaries. Cell Tissue Res (2013) 0.89
Detection of telomerase RNA in the plasma of patients with breast cancer, malignant melanoma or thyroid cancer. Oncol Rep (2004) 0.88
Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med Genet (2008) 0.87
Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients. Langenbecks Arch Surg (2004) 0.87
KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. Int J Oncol (2010) 0.87
Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol (2010) 0.87
Is patient's age a prognostic factor for follicular thyroid carcinoma in the TNM classification system? Thyroid (2005) 0.86
Role of ultrasound in the preoperative staging of patients with breast cancer. Eur Radiol (2005) 0.86
Extent of thyroidectomy and lymphadenectomy in 254 patients with papillary thyroid microcarcinoma: a single-institution experience. Ann Surg Oncol (2009) 0.86
Lack of association between methylenetetrahydrofolate reductase genetic polymorphisms and postmenopausal breast cancer risk. Mol Med Rep (2010) 0.84
Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. Int J Cancer (2014) 0.84
Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families. BMC Med Genet (2008) 0.84
Combined effect of CYP1B1, COMT, GSTP1, and MnSOD genotypes and risk of postmenopausal breast cancer. J Gynecol Oncol (2011) 0.84
Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs. Vaccine (2007) 0.83
Factors correlated to successful surgical treatment of 181 non-palpable invasive breast carcinomas. Breast (2009) 0.83
Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid. Med Sci Monit (2008) 0.83
Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis. Radiol Oncol (2011) 0.83
Predictive factors of carcinoma in 279 patients with Hürthle cell neoplasm of the thyroid gland. J Surg Oncol (2010) 0.83
Optimization of an RNA isolation procedure from plasma samples. Int J Mol Med (2007) 0.83
Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity. BMC Immunol (2010) 0.82
BRCA2 gene mutations in Slovenian male breast cancer patients. Genet Test (2008) 0.82
Class C CpG oligodeoxynucleotides as a single agent and in combination with radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors. Innate Immun (2009) 0.82
Touch imprint cytology of the sentinel lymph nodes might not be indicated in early breast cancer patients with ultrasonically uninvolved axillary lymph nodes. Ann Surg Oncol (2008) 0.81
The role of preoperative ultrasonography in reducing the number of sentinel lymph node procedures in melanoma. Melanoma Res (2004) 0.80
Ljubljana nomograms for predicting the likelihood of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel lymph node. Breast Cancer Res Treat (2010) 0.80
The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. BMC Med Genet (2011) 0.80
Prognostic heterogeneity after the excision of lymph node metastases in patients with cutaneous melanoma. Surg Oncol (2009) 0.79
Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer (2011) 0.79
Lower tumour burden and better overall survival in melanoma patients with regional lymph node metastases and negative preoperative ultrasound. Radiol Oncol (2011) 0.79
Adjuvant radiotherapy for palpable melanoma metastases to the groin: when to irradiate? Int J Radiat Oncol Biol Phys (2011) 0.78
Epidemiological trends of hormone-related cancers in Slovenia. Arh Hig Rada Toksikol (2016) 0.77
Putative mesenchymal stem cells isolated from adult human ovaries. J Assist Reprod Genet (2014) 0.77
Tumor vaccine composed of CpG ODN class C and irradiated tumor cells up-regulates the expression of genes characteristic of mature dendritic cells and of memory cells. Int J Oncol (2011) 0.77
Age at menarche and menopause is not associated with two common genetic variants in the methylenetetrahydrofolate reductase (MTHFR) gene. Eur J Contracept Reprod Health Care (2011) 0.77
High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families. Croat Med J (2006) 0.76
Estrogen metabolism genotypes, use of long-term hormone replacement therapy and risk of postmenopausal breast cancer. Oncol Rep (2011) 0.76
Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer. Radiol Oncol (2011) 0.76
Digital evaluation of breast cosmesis after breast-conserving treatment: end of the beginning. Breast (2007) 0.75
Different natural course of disease in patients with melanoma. J Clin Oncol (2009) 0.75
Multi-institutional comparison of non-sentinel lymph node predictive tools in breast cancer patients with high predicted risk of further axillary metastasis. Pathol Oncol Res (2012) 0.75